Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy

Yadav, Dokkari Nagalaxmi and Ali, Mohammad Sadik and Thanekar, Ajinkya Madhukar and Pogu, Sunil Venkanna and Rengan, Aravind Kumar (2022) Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy. Molecular Pharmaceutics, 19. pp. 1-21. ISSN 1543-8384

Text
Molecular_Pharmaceutics_1.pdf - Published Version
Restricted to Registered users only
Download (9MB) | Request a copy

Abstract

RNA interference (RNAi) has increased the possibility of restoring RNA drug targets for cancer treatment. Small interfering RNA (siRNA) is a promising therapeutic RNAi tool that targets the defective gene by inhibiting its mRNA expression and stopping its translation. However, siRNAs have flaws like poor intracellular trafficking, RNase degradation, rapid kidney filtration, off-targeting, and toxicity, which limit their therapeutic efficiency. Nanocarriers (NCs) have been designed to overcome such flaws and increase antitumor activity. Combining siRNA and anticancer drugs can give synergistic effects in cancer cells, making them a significant gene-modification tool in cancer therapy. Our discussion of NCs-mediated siRNA delivery in this review includes their mechanism, limitations, and advantages in comparison with naked siRNA delivery. We will also discuss organic NCs (polymers and lipids) and inorganic NCs (quantum dots, carbon nanotubes, and gold) that have been reported for extensive delivery of therapeutic siRNA to tumor sites. Finally, we will conclude by discussing the studies based on organic and inorganic NCs-mediated siRNA drug delivery systems conducted in the years 2020 and 2021. © 2022 American Chemical Society.

[error in script]

IITH Creators:

IITH Creators	ORCiD
Rengan, Aravind Kumar	https://orcid.org/0000-0003-3994-6760

Item Type:

Article

Additional Information:

The authors thank MHRD IMPRINT (4291), ICMR (No. 35/1/2020-GIA/Nano/BMS), DST-AMT (DST/TDT/AMT/2017/227), and SERB-CRG (CRG/2020/005069) for funding the project grants. D.N.Y. acknowledges DST-INSPIRE (DST/INSPIRE/03/2019/001517) for funding her fellowship. Fellowship from the Council of Scientific and Industrial Research CSIR, (09/1001(0092)/2021-EMR-1) and (09/1001(0080)/2020-EMR-1) of the Government of India is gratefully acknowledged by M.S.A. and A.M.T. A fellowship from the Department of Biotechnology, Ministry of Science & Technology, Government of India DBT, (DBT/2020/IIT-H/1356) is gratefully acknowledged by the author S.V.P. The authors also acknowledge our lab mates Rajalakshmi P. S., Sri Amruthaa Sankaranarayanan, and Monika Pebam for their help during the submission process. and and the graphical abstract (table of contents graphic) were created using the licensed version of Biorender software by the author D.N.Y.; , , and were adapted from the review and research papers w ...

Uncontrolled Keywords:

cancer; nanocarriers; RNAi; siRNA delivery; therapy

Subjects:

Biomedical Engineering

Divisions:

Department of Biomedical Engineering

Depositing User:

Ms Palak Jain

Date Deposited:

22 May 2023 09:28

Last Modified:

22 May 2023 09:28